DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.
about
Immunomodulation of antigen presenting cells promotes natural regulatory T cells that prevent autoimmune diabetes in NOD mice.In vivo expression of HGF/NK1 and GLP-1 From dsAAV vectors enhances pancreatic ß-cell proliferation and improves pathology in the db/db mouse model of diabetes.Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.Glucagon-like peptide-1 gene therapyA practical guide to genetic engineering of pancreatic β-cells in vivo: getting a grip on RIP and MIP.Polymer-based delivery of glucagon-like Peptide-1 for the treatment of diabetes.Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy.Treatment of diabetes with glucagon-like peptide-1 gene therapy.GLP-1-mediated gene therapy approaches for diabetes treatment.A novel pancreatropic coxsackievirus vector expressing glucagon-like peptide 1 reduces hyperglycemia in streptozotocin-treated mice.Overexpression of peroxisome proliferator-activated receptor α in pancreatic β-cells improves glucose tolerance in diet-induced obese mice.Characterization of vector-based delivery of neurogenin-3 in murine diabetes.Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector.dsAAV8-mediated gene transfer and β-cell expression of IL-4 and β-cell growth factors are capable of reversing early-onset diabetes in NOD mice.The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation.
P2860
Q34166274-991FFD53-7B04-41C2-9F6E-C7B4FF316CCBQ34355256-684B5E05-E846-46C5-8DD8-26EE31B6D122Q34706913-BE1BC1E0-9151-40AD-B611-6D5BAD8B185AQ35071227-FA1601A5-6435-4A12-928F-F1D6D983A787Q35222861-EDD44C90-6B0F-4930-AA15-67F356CC32B0Q36014423-0BF32EEB-B342-484E-8C85-2B77FFA8FDE4Q37137787-58707497-A864-4C1C-9DBF-92F9A95C830BQ37804398-8DB47D75-7B11-4F76-AEEC-628B778B39FEQ38199215-B427C129-575F-4A18-B6B2-432D5BEFF424Q38961417-FF66A59C-7B5F-434E-B7D9-43502C2505E4Q39264494-EFD24F13-03CD-49A3-B9D5-F36386593413Q41893785-3D4ACE61-6417-42D4-8E7A-B64A2E9D9822Q45862933-80155FEF-6758-4BF6-9CD1-0C42DCF8E396Q45875053-1700A514-292B-404B-9F88-347CEF30CDD8Q54463919-EEE8B889-82C3-425E-9461-C03C545E0D18
P2860
DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
DsAAV8-mediated expression of ...... reptozotocin-induced diabetes.
@en
DsAAV8-mediated expression of ...... reptozotocin-induced diabetes.
@nl
type
label
DsAAV8-mediated expression of ...... reptozotocin-induced diabetes.
@en
DsAAV8-mediated expression of ...... reptozotocin-induced diabetes.
@nl
prefLabel
DsAAV8-mediated expression of ...... reptozotocin-induced diabetes.
@en
DsAAV8-mediated expression of ...... reptozotocin-induced diabetes.
@nl
P2093
P2860
P356
P1433
P1476
DsAAV8-mediated expression of ...... reptozotocin-induced diabetes.
@en
P2093
P2860
P2888
P304
P356
10.1038/GT.2009.143
P577
2009-10-29T00:00:00Z
P5875
P6179
1039217151